Prognostic significance of the preoperative lymphocyte‑to‑monocyte ratio in patients with colorectal cancer

  • Authors:
    • Masatsune Shibutani
    • Kiyoshi Maeda
    • Hisashi Nagahara
    • Yasuhito Iseki
    • Tetsuro Ikeya
    • Kosei Hirakawa
  • View Affiliations

  • Published online on: December 12, 2016     https://doi.org/10.3892/ol.2016.5487
  • Pages: 1000-1006
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A correlation between the lymphocyte‑to‑monocyte ratio (LMR) and the survival of patients with hematological malignancies has been reported previously. However, there have been few studies investigating the prognostic significance of LMR in patients with solid tumors. The aim of the present study was to evaluate the prognostic significance of preoperative LMR in patients with colorectal cancer (CRC). A total of 189 patients undergoing potentially curative surgery for CRC were enrolled. The LMR was calculated from preoperative blood samples by dividing absolute lymphocyte count by absolute monocyte count. A cut‑off value of 4.8 was set based on the receiver operating characteristic curve; 116 patients were classified as high‑LMR, and 73 patients classified as low‑LMR. The high‑LMR group exhibited significantly better relapse‑free survival (P=0.0018) and overall survival (P=0.0127) rates than the low‑LMR group. According to the multivariate analysis of survival, preoperative LMR was identified as an independent prognostic factor for relapse‑free survival (P=0.041) and overall survival (P=0.031). Therefore, preoperative LMR is a useful prognostic marker in patients with CRC.

Introduction

Colorectal cancer (CRC) is the third most common cancer and fourth leading cause of cancer-associated mortality worldwide (1). Despite advances in surgical procedures and adjuvant chemotherapy, 20–25% of patients still experience relapse following curative surgery (2). The Union for International Cancer Control (UICC) tumor node metastasis (TNM) staging system (3) is currently the most reliable indicator of patient prognosis and is widely used amongst practitioners. However, there are differences in patient prognosis even within the same TNM stage. Therefore, more reliable markers are required to improve predictions of cancer recurrence and patient survival.

It has previously been reported that inflammation is important in determining cancer progression (4,5). Inflammation-based indices, such as the C-reactive protein level, Glasgow prognostic score, and neutrophil-to-lymphocyte ratio; are useful for predicting the prognosis of patients with CRC as well as various other types of cancer (69). Recent studies investigating various types of malignancies have demonstrated a correlation between the lymphocyte-to-monocyte ratio (LMR), which also reflects the degree of systemic inflammation, and patient survival (1014). However, the prognostic value of the LMR has mainly been investigated in patients with hematological malignancies, with few reports focusing on patients with solid tumors. Therefore, the aim of this retrospective study was to evaluate the prognostic significance of preoperative LMR in patients with CRC who are able to undergo potentially curative surgery.

Materials and methods

Patients

A total of 189 patients with CRC were enrolled. All patients underwent potentially curative surgery for CRC in the Department of Surgical Oncology, Osaka City University, between January 2007 and December 2009. Patients who received preoperative therapy, underwent emergency surgery for perforation/obstruction, or who had inflammatory bowel disease were excluded from the study.

The patient characteristics are presented in Table I. Included in the study were 107 males and 82 females, and median patient age at initial surgery was 68 years old (range, 26–86 years old). A total of 112 patients had primary tumors located in the colon and 77 had primary tumors located in the rectum. Resected specimens were pathologically classified according to the UICC TNM classification of malignant tumors, ver. 7 (3). The distribution of cancer stages was as follows: stage I, 63; stage II, 65; stage III, 61 patients. All patients underwent regular physical examinations and blood tests. The levels of tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), were measured, and mandatory screening was performed using colonoscopy and computed tomography until December 2014 (60 months following surgery) or patient mortality.

Table I.

Patient characteristics.

Table I.

Patient characteristics.

CharacteristicNo. patients
Gender
  Male107
  Female  82
Age, years
  Median (range)68 (26–86)
Location of primary tumor
  Colon112
  Rectum  77
Tumor depth
  T1-3150
  T4  39
Tumor diameter, cm
  Median (range)4.0 (0.2–11.0)
Histological type
  Well or moderately differentiated169
  Poorly differentiated or mucinous  16
Lymphatic involvement
  Negative  76
  Positive113
Venous involvement
  Negative163
  Positive  21
Lymph node metastases
  Negative126
  Positive  63
Stagea
  I  63
  II  65
  III  61
Lymphocyte count, per mm3
  Median (range)1690 (432–3891)
Monocyte count, per mm3
  Median (range)324 (28–792)

a According to the Union for International Cancer Control Tumor- Node-Metastasis Classification of Malignant Tumors (3).

Blood sample analysis

Preoperative blood samples were obtained at the time of diagnosis prior to surgery. The differential white blood cell count was analyzed using the Sysmex XE-5000 automated hematology analyzer™ (Sysmex, Kobe, Japan) following the manufacturer protocol. LMR was calculated from the preoperative blood samples by dividing the absolute lymphocyte count by the absolute monocyte count.

Statistical analysis

A receiver operating characteristic (ROC) curve was used to determine an appropriate cut-off value. All patients were classified into two groups according to the preoperative LMR. The significance of associations between preoperative LMR and clinicopathological characteristics was analyzed using χ2 test and Fisher's exact test. Duration of survival was calculated according to the Kaplan-Meier method. Differences between survival curves were assessed with the log-rank test. A multivariate analysis was performed according to the Cox proportional hazards model, and all statistical analyses were performed using the SPSS software package (SPSS Inc., Tokyo, Japan). P<0.05 was considered to indicate a statistically significant difference.

Ethical considerations

The current study conformed to the provisions of the Declaration of Helsinki and was approved by the ethics committee of Osaka City University. All patients were informed of the investigational nature of this study and provided written informed consent.

Results

Survival analysis according to the lymphocyte/monocyte count

The median preoperative lymphocyte count was 1,690/mm3 (range, 432–3,891), and 1,000 mm3 was set as the cut-off value, in accordance with previous studies (15). Following the lymphocyte count, 171 patients were placed into the high-lymphocyte group and 18 patients into the low-lymphocyte group. Relapse-free survival rate and overall survival rate were significantly lower in the low-lymphocyte group compared with the high-lymphocyte group (Fig. 1, relapse-free survival; P=0.0131; Fig. 2, overall survival; P=0.0314).

The median preoperative monocyte count was 324/mm3 (range, 28–792), and 300 was set as the cut-off value, based on previous reports (16). A total of 76 patients were placed into the high-monocyte group and 113 patients into the low-monocyte group. Both the relapse-free survival rate and the overall survival rate were significantly lower in the high-monocyte group compared with the low-monocyte group (Fig. 3, relapse-free survival; P=0.0243; Fig. 4, overall survival; P=0.0444).

Cut-off value for the LMR

The median preoperative LMR was 5.429 (range, 1.494–57.500). The continuous variable LMR was used as the test variable and the 5-year rate survival as the state variable. The cut-off value for the preoperative LMR was investigated using the ROC curve, and was determined as 4.8 (the sensitivity was 64.1% and the specificity was 63.2%; Fig. 5). Based on this cut-off value, 116 patients were classified into the high-LMR group and 73 patients were classified into the low-LMR group.

Correlation between the LMR and clinicopathological parameters

The associations between preoperative LMR and clinicopathological parameters are shown in Table II. The only significant relationship identified was between preoperative LMR and lymphatic involvement (P=0.013, Table II).

Table II.

Associations between preoperative LMR and clinicopathological factors.

Table II.

Associations between preoperative LMR and clinicopathological factors.

LMR

FactorsHighLowP-value
Age, years 0.073
  <707034
  ≥704639
Gender 0.099
  Male6047
  Female5626
Tumor location 0.880
  Colon6844
  Rectum4829
Tumor depth 0.196
  T1-39654
  T42019
Tumor diameter, cm 0.063
  <57537
  ≥53834
Histological type 0.789
  Well/moderately differentiated10564
  Poorly differentiated/mucinous  9  7
Lymphatic involvement 0.013
  Negative5219
  Positive6152
Venous involvement 0.352
  Negative9865
  Positive15  6
Lymph node metastasis 0.156
  Negative8244
  Positive3429
Preoperative CEA (>5 ng/ml) 1.000
  Negative7747
  Positive3824
Stagea 0.139
  I4419
  II4025
  III3229
Adjuvant chemotherapy 0.881
  No6439
  Yes5234

{ label (or @symbol) needed for fn[@id='tfn2-ol-0-0-5487'] } LMR, lymphocyte-to-monocyte ratio; CEA, carcinoembryonic antigen.

a According to the Union for International Cancer Control Tumor-Node-Metastasis Classification of Malignant Tumors (3). Bold indicates a statistically significant difference (P<0.05).

Survival analysis according to the LMR

The relapse-free survival rate was significantly lower in the low-LMR group compared with that of the high-LMR group (P=0.0018; Fig. 6), as was overall survival rate (P=0.0127; Fig. 7).

Furthermore, even in an analysis limited to the patients with a normal lymphocyte count (>1,000/mm3), relapse-free survival rate was significantly lower in the low-LMR group than in the high-LMR group (P=0.0071; Fig. 8), and overall survival rate tended to be lower in the low-LMR group than in the high-LMR group, though this difference was not significant. (P=0.0792; Fig. 9).

Prognostic factors influencing relapse-free/overall survival

The associations between relapse-free survival and various clinicopathological factors are presented in Table III. According to a univariate analysis, there were significant correlations between relapse-free survival and tumor diameter, histological type, lymphatic involvement, lymph node metastasis, preoperative CEA levels and the preoperative LMR (all P<0.05). Multivariate analysis indicated that only preoperative LMR was an independent risk factor for a poor relapse-free survival. The associations between overall survival and various clinicopathological factors are presented in Table IV. According to a univariate analysis, there were significant correlations between overall survival and both lymph node metastasis and preoperative LMR. In addition, a multivariate analysis indicated that lymph node metastasis and preoperative LMR were independent risk factors for poor overall survival.

Table III.

Associations between relapse-free survival and various clinicopathological factors.

Table III.

Associations between relapse-free survival and various clinicopathological factors.

Univariate analysisMultivariate analysis


FactorsHazard Ratio95% CIP-valueHazard Ratio95% CIP-value
Age (>70 years vs. ≤70 years)1.4330.764–2.6850.262
Gender (female vs. male)1.5750.809–3.0640.181
Location of primary tumor (rectum vs. colon)1.5450.824–2.9850.175
Tumor depth (T4 vs. T1-3)1.3960.680–2.8650.363
Tumor diameter (>5 cm vs. ≤5 cm)2.4211.256–4.6690.0081.2590.597–2.6550.546
Histological type (poor, mucinous vs. well, moderately)2.7771.222–6.3080.0151.6070.678–3.8050.281
Lymphatic involvement (positive vs. negative)3.2111.417–7.2760.0051.9460.676–5.6000.217
Venous involvement (positive vs. negative)1.7820.787–4.0390.166
Lymph node metastasis (positive vs. negative)3.3621.775–6.366 <0.0012.0410.904–4.6060.086
Preoperative CEA (>5 ng/ml vs. ≤5 ng/ml)2.5901.369–4.8990.0031.9230.913–4.0540.086
Preoperative LMR (≥4.8 vs. <4.8)2.6571.403–5.0330.0032.0511.028–4.0900.041

[i] CI, confidence interval; CEA, carcinoembryonic antigen; LMR, lymphocyte-to-monocyte ratio. Bold denotes a statistically significant result (P<0.05).

Table IV.

Correlations between overall survival and various clinicopathological factors.

Table IV.

Correlations between overall survival and various clinicopathological factors.

Univariate analysisMultivariate analysis


FactorsHazard Ratio95% CIP-valueHazard ratio95% CIP-value
Age (>70 years vs. ≤70 years)1.3860.562–3.4160.479
Gender (female vs. male)1.7130.651–4.5080.275
Location of primary tumor (rectum vs. colon)1.9090.767–4.7480.164
Tumor depth (T4 vs. T1-3)0.6890.201–2.3650.553
Tumor diameter (>5 cm vs. ≤5 cm)1.2240.492–3.0470.664
Histological type (poor, mucinous vs. well, moderate)1.1720.271–5.0780.832
Lymphatic involvement (positive vs. negative)2.3790.790–7.1690.124
Venous involvement (positive vs. negative)2.6630.959–7.3960.060
Lymph node metastasis (positive vs. negative)2.8141.132–6.9960.0262.5331.014–6.3280.047
Preoperative CEA (>5 ng/ml vs. ≤5 ng/ml)2.0080.815–4.9460.130
The preoperative LMR (≥4.8 vs. <4.8)3.0811.212–7.8300.0182.8051.098–7.1630.031

[i] CI, confidence interval; CEA, carcinoembryonic antigen; LMR, lymphocyte-to-monocyte ratio. Bold denotes a statistically significant result (P<0.05).

Discussion

Inflammation and cancer are closely related. Inflammation is caused not only by the systemic reaction of the host to the tumor, but also by inflammatory cytokines and chemokines released by cancer cells, and tumor-associated leukocytes that cause tumor growth, invasion, metastasis and suppression of the host immune system (4,5,17,18). Thus, inflammation reflects cancer progression, and the significance of systemic inflammatory markers in predicting the survival of patients with CRC, as well as other malignancies, has previously been reported. LMR, which consists of the peripheral lymphocyte and monocyte counts, also reflects systemic inflammation.

Lymphocytes serve an important role in tumor suppression. Previous studies have demonstrated a correlation between lymphopenia and poor prognosis of patients with various types of cancer (15,19). Lymphocytes induce cytotoxic cell death and produce cytokines that inhibit cancer cell proliferation and metastatic activity (4,20,21). The absolute peripheral lymphocyte count is assumed to reflect the degree of responsiveness of the entire immune system of a patient (15,22). Therefore, a low peripheral lymphocyte count may result in a weak and insufficient immunological reaction to the tumor, thus promoting tumor progression and metastasis (23).

By contrast, monocytes play an important role in tumor progression (4,24). A correlation between monocytosis and poor prognosis in different types of cancer has previously been observed (16,2527). Monocytes represent a source of chemokines and cytokines that contribute to inflammation (28). Inflammation in the cancer microenvironment promotes tumor progression and metastasis (29). Moreover, tumor-associated macrophages (TAMs), derived from circulating monocytes (30), cause migration, intravasation, tumor cell invasion, tumor-associated angiogenesis, and the suppression of the anti-tumor immune system (4,3133). The absolute peripheral monocyte count reflects the formation and/or presence of TAMs (34), thus a high peripheral monocyte count is responsible for a high tumor burden. Therefore, low LMR reflects insufficient antitumor immunity and an elevated tumor burden, and is associated with poor patient prognosis.

In previous studies, both the lymphocyte and the monocyte count have been reported as prognostic factors for the survival of patients with various malignancies, and this was confirmed in the present study. Furthermore, the prognostic significance of LMR was investigated, and was demonstrated to be an accurate prognostic marker. Even in an analysis limited to patients with a normal lymphocyte count, the LMR identified patients with a poor prognosis. Therefore, the LMR is considered to be a more accurate prognostic marker than the lymphocyte count alone.

The cut-off value for the LMR used in the present study was different from that of previous studies. A cut-off value of 4.8 was set based on a ROC analysis, and was higher than cut-off values used in previous studies, which ranged between 2.14–4.19 (1214,35). Thus, although LMR is a useful prognostic marker for various solid tumors, the optimum cut-off value for the LMR may differ according to the organ, stage or end point (such as disease-free survival, progression-free survival or overall survival).

There are several limitations associated with the present study: i) A relatively small number of patients were evaluated; ii) the study design was retrospective; iii) the results obtained were not validated in another population; iv) potential confounding factors, such as infection, ischemia or acute coronary disease, which may affect the white blood cell count, were not assessed; v) the optimum cut-off value for the preoperative LMR remains unknown, although 4.8 was set as the cut-off value using the results of a ROC analysis. Therefore, a large prospective study is required to confirm the findings of the current study.

In conclusion, preoperative LMR may be a useful prognostic marker in patients with CRC able to undergo potentially curative surgery, and assessing the LMR may enable more informed decisions regarding choice of therapeutic strategies to be made. It is quick and easy to obtain a peripheral blood cell count, therefore, measuring preoperative LMR may become a novel clinical biomarker for patients with CRC.

Acknowledgements

The authors thank Brian Quinn, who provided medical writing services on behalf of JMC, Ltd.

References

1 

Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Edge S, Byrd D, Compton C, Fritz A, Greene F and Trotti A: AJCC Cancer Staging Manual. 7th. Springer; New York: pp. 237–246. 2010

3 

Sobin LH, Gospodarowicz MK and Wittekind C: UICC. TNM Classification of Malignant Tumors. 7. Wiley-Liss; New York: 2009

4 

Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI

6 

Shibutani M, Maeda K, Nagahara H, Ohtani H, Sugano K, Ikeya T, Kimura K, Amano R, Kubo N, Tanaka H, et al: Elevated preoperative serum C-reactive protein levels are associated with poor survival in patients with colorectal cancer. Hepatogastroenterology. 61:2236–2240. 2014.PubMed/NCBI

7 

Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y and Hirakawa K: A high preoperative neutrophil- to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res. 33:3291–3294. 2013.PubMed/NCBI

8 

Walsh SR, Cook EJ, Goulder F, Justin TA and Keeling NJ: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 91:181–184. 2005. View Article : Google Scholar : PubMed/NCBI

9 

Maeda K, Shibutani M, Otani H, Nagahara H, Sugano K, Ikeya T, Amano R, Kimura K, Sakurai K, Kubo N, et al: Prognostic value of preoperative inflammation-based prognostic scores in patients with stage IV colorectal cancer who undergo palliative resection of asymptomatic primary tumors. Anticancer Res. 33:5567–5573. 2013.PubMed/NCBI

10 

Li YL, Pan YY, Jiao Y, Ning J, Fan YG and Zhai ZM: Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. Ann Hematol. 93:617–626. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, et al: Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 157:321–330. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T and Gerger A: The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 110:435–440. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Huang Y and Feng JF: Low preoperative lymphocyte to monocyte ratio predicts poor cancer-specific survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther. 8:137–145. 2015.PubMed/NCBI

14 

Hu P, Shen H, Wang G, Zhang P, Liu Q and Du J: Prognostic significance of systemic inflammation-based lymphocyte- monocyte ratio in patients with lung cancer: Based on a large cohort study. PLoS One. 9:e1080622014. View Article : Google Scholar : PubMed/NCBI

15 

Cézé N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E and Lecomte T: Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 68:1305–1313. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M and Kitano S: Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery. 139:755–764. 2006. View Article : Google Scholar : PubMed/NCBI

17 

Balkwill FR: The chemokine system and cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar : PubMed/NCBI

18 

Guthrie GJ, Roxburgh CS, Horgan PG and McMillan DC: Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev. 39:89–96. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, et al: Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 69:5383–5391. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Terzié J, Grivennikov S, Karin E and Karin M: Inflammation and colon cancer. Gastroenterology. 138:2101–2114. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Lin EY and Pollard JW: Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer. 90:2053–2058. 2010. View Article : Google Scholar

22 

Kitayama J, Yasuda K, Kawai K, Sunami E and Nagawa H: Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer. 11:642011. View Article : Google Scholar : PubMed/NCBI

23 

Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT and Whiteside TL: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 8:2553–2562. 2002.PubMed/NCBI

24 

Evani SJ, Prabhu RG, Gnanaruban V, Finol EA and Ramasubramanian AK: Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow. FASEB J. 27:3017–3029. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Tominaga M, Okunaga R, Shibata K, Ohta M and Kitano S: Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection. J Gastrointest Surg. 11:596–602. 2007. View Article : Google Scholar : PubMed/NCBI

26 

Haruki K, Shiba H, Fujiwara Y, Furukawa K, Wakiyama S, Ogawa M, Ishida Y, Misawa T and Yanaga K: Perioperative change in peripheral blood monocyte count may predict prognosis in patients with colorectal liver metastasis after hepatic resection. J Surg Oncol. 106:31–35. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, Kim MK, Kim HJ, Kim TJ, Lee JW, et al: Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag level. Gynecol Oncol. 124:92–97. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM and Kusmartsev S: Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 130:1109–1119. 2012. View Article : Google Scholar : PubMed/NCBI

29 

Landskron G, De la Fuente M, Thuwajit P, Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014:1491852014. View Article : Google Scholar : PubMed/NCBI

30 

Mantovani A, Bottazzi B, Colotta F, Sozzani S and Ruco L: The origin and function of tumor-associated macrophages. Immunol Today. 13:265–270. 1992. View Article : Google Scholar : PubMed/NCBI

31 

Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78. 2004. View Article : Google Scholar : PubMed/NCBI

32 

Condeelis J and Pollard JW: Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI

33 

Lievense LA, Bezemer K, Aerts JG and Hegmans JP: Tumor-associated macrophages in thoracic malignancies. Lung Cancer. 80:256–262. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, Trajanoski S, Stojakovic T, Eberhard K, Leithner A and Pichler M: The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 135:362–370. 2014. View Article : Google Scholar : PubMed/NCBI

35 

Go SI, Kim RB, Song HN, Kang MH, Lee US, Choi HJ, Lee SJ, Cho YJ, Jeong YY, Kim HC, et al: Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. Med Oncol. 31:3232014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

February-2017
Volume 13 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T and Hirakawa K: Prognostic significance of the preoperative lymphocyte‑to‑monocyte ratio in patients with colorectal cancer. Oncol Lett 13: 1000-1006, 2017
APA
Shibutani, M., Maeda, K., Nagahara, H., Iseki, Y., Ikeya, T., & Hirakawa, K. (2017). Prognostic significance of the preoperative lymphocyte‑to‑monocyte ratio in patients with colorectal cancer. Oncology Letters, 13, 1000-1006. https://doi.org/10.3892/ol.2016.5487
MLA
Shibutani, M., Maeda, K., Nagahara, H., Iseki, Y., Ikeya, T., Hirakawa, K."Prognostic significance of the preoperative lymphocyte‑to‑monocyte ratio in patients with colorectal cancer". Oncology Letters 13.2 (2017): 1000-1006.
Chicago
Shibutani, M., Maeda, K., Nagahara, H., Iseki, Y., Ikeya, T., Hirakawa, K."Prognostic significance of the preoperative lymphocyte‑to‑monocyte ratio in patients with colorectal cancer". Oncology Letters 13, no. 2 (2017): 1000-1006. https://doi.org/10.3892/ol.2016.5487